Aktis Oncology

Miniprotein-based alpha radiopharmaceuticals for oncology

a16zPublic

What they do

Problem

Cancer patients need more effective and targeted therapies to destroy tumors while minimizing damage to healthy tissue.

Solution

The company develops miniprotein-based alpha-emitting radiopharmaceuticals designed to deliver targeted radiation to cancer cells.

Who it's for

Oncology clinicians and hospital systems that treat cancer patients, via biopharma development and clinical use.